Dublin, Jan. 25, 2019 (GLOBE NEWSWIRE) -- The "Immuno-oncology Development Trends and Opportunities" report has been added to ResearchAndMarkets.com's offering.

"Immuno-oncology Development Trends and Opportunities", report provides an overview of current clinical development trends for Immuno-Oncology (IO) within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including a history of recent approvals, indications currently being explored for Immuno-Oncology (IO) agents of all modalities, targets being selected for Immuno-Oncology (IO) therapies, and combination strategies being investigated for approved Immuno-Oncology (IO) agents.

In addition, the report provides disease overviews, epidemiology, current recommended treatment regimens and Immuno-Oncology (IO) approvals, and Immuno-Oncology (IO) clinical trial trends for 17 indications identified on the basis of representing the largest commercial opportunities for Immuno-Oncology (IO) agents. Clinical trial trends analyze ongoing trials by sponsor type and modality, as well as ongoing combination trials for approved Immuno-Oncology (IO) therapies.

Immuno-Oncology (IO) is the treatment of cancer with therapies that stimulate or suppress the body's own immune system. Several distinct modalities of IO therapy exist, including bispecific T-cell engaging monoclonal antibodies, cellular immunotherapy and adoptive cellular therapy, cancer vaccines, checkpoint modulating monoclonal antibodies, and oncolytic viruses.

Scope

• Quotes from 13 US-, 5EU-, and Japan-based key opinion leaders
• Summary of IO product definitions and classifications
• Overview of development opportunities for IO agents across indications, including emerging indications and clinical targets, and novel combination strategies
• Outline of 17 key indications for IO agents, including current EU and US guideline recommendations, IO's current place in the treatment algorithm, and a review of ongoing clinical trials
• Call-outs of key information and details
• Insight from the researcher's specialist oncology analysts.

Reasons to buy

• Develop business strategies by understanding the trends shaping and driving IO in the 8MM.
• Drive revenues by understanding the key trends, innovative combination strategies and indications likely to impact the IO market in the future.
• Design your development strategy through a review of potential novel targets or combinations across indications.
• Organize your sales and marketing efforts by understanding IO combination approaches across indications that present maximum opportunities for consolidations, investments, and strategic partnerships.
• Develop strategies by understanding expert perceptions of unmet needs in key indications in oncology, and the potential for IO agents to meet those needs.

Key Topics Covered:

1. Preface
1.1 Related Reports
1.2 Upcoming Reports
1.3 Abbreviations

2. Executive Summary

3. Introduction
3.1 Immuno-oncology Overview
3.2 IO Product Definition and Classification
3.3 Report Structure
3.4 Key Indications for IO Agents

4. Development Opportunities for IO Agents
4.1 Timeline of Recent IO Approvals in the 8MM
4.2 Clinical Development of IO Agents Across Indications
4.2.1 IO Agents in Development by MOA and by Indication
4.2.2 Ongoing Clinical Trials by Sponsor Type
4.2.3 Key and Emerging Indications for Checkpoint Modulators
4.2.4 Key and Emerging Indications for Bispecific Antibodies
4.2.5 Key and Emerging Indications for Cancer Vaccines
4.2.6 Key and Emerging Indications for Cell Therapies
4.2.7 Key and Emerging Indications for Oncolytic Viruses
4.3 Combinations of Approved IO Agents
4.4 Clinical Targets and Predictive Biomarkers for IO Agents
4.4.1 Clinical Targets for Checkpoint Modulators
4.4.2 Clinical Targets for Bispecific Antibodies
4.4.3 Clinical Targets for Cell Therapies
4.4.4 Predictive Biomarkers for IO Agents

5. Acute Lymphoblastic Leukemia (ALL)
5.1 Disease Overview and Epidemiology
5.2 Current Treatment Guidelines and IO Approvals for ALL
5.3 Clinical Trial Activity in ALL
5.4 IO Marketed Product Lifecycle Development in ALL

6. Bladder Cancer
6.1 Disease Overview and Epidemiology
6.2 Current Treatment Guidelines and IO Approvals for Bladder Cancer
6.3 Clinical Trial Activity in Bladder Cancer
6.4 IO Marketed Product Lifecycle Development in Bladder Cancer

7. Breast Cancer
7.1 Disease Overview and Epidemiology
7.2 Current Treatment Guidelines and IO Approvals for Breast Cancer
7.3 Clinical Trial Activity in Breast Cancer

8. Chronic Lymphocytic Leukemia (CLL)
8.1 Disease Overview and Epidemiology
8.2 Current Treatment Guidelines and IO Approvals for CLL
8.3 Clinical Trial Activity in CLL

9. Colorectal Cancer
9.1 Disease Overview and Epidemiology
9.2 Current Treatment Guidelines and IO Approvals for Colorectal Cancer
9.3 Clinical Trial Activity in Colorectal Cancer
9.4 IO Marketed Product Lifecycle Development in Colorectal Cancer

10. Gastric and Gastroesophageal Cancer (GA/GEJAC)
10.1 Disease Overview and Epidemiology
10.2 Current Treatment Guidelines and IO Approvals for GA/GEJAC
10.3 Clinical Trial Activity in GA/GEJAC
10.4 IO Marketed Product Lifecycle Development in GA/GEJAC

11. Glioblastoma
11.1 Disease Overview and Epidemiology
11.2 Current Treatment Guidelines and IO Approvals for Glioblastoma
11.3 Clinical Trial Activity in Glioblastoma

12. Head and Neck Cancer
12.1 Disease Overview and Epidemiology
12.2 Current Treatment Guidelines and IO Approvals for Head and Neck Cancer
12.3 Clinical Trial Activity in Head and Neck Cancer
12.4 IO Marketed Product Lifecycle Development in Head and Neck Cancer

13. Hepatocellular Carcinoma (HCC)
13.1 Disease Overview and Epidemiology
13.2 Current Treatment Guidelines and IO Approvals for HCC
13.3 Clinical Trial Activity in HCC
13.4 IO Marketed Product Lifecycle Development in HCC

14. Melanoma
14.1 Disease Overview and Epidemiology
14.2 Current Treatment Guidelines and IO Approvals for Melanoma
14.3 Clinical Trial Activity in Melanoma
14.4 IO Marketed Product Lifecycle Development in Melanoma

15. Multiple Myeloma
15.1 Disease Overview and Epidemiology
15.2 Current Treatment Guidelines and IO Approvals in Multiple Myeloma
15.3 Clinical Trial Activity in Multiple Myeloma

16. Non-Hodgkin Lymphoma (NHL)
16.1 Disease Overview and Epidemiology
16.2 Current Treatment Guidelines and IO Approvals for NHL
16.3 Clinical Trial Activity in NHL
16.4 IO Marketed Product Lifecycle Development in NHL

17. Non-Small Cell Lung Cancer (NSCLC)
17.1 Disease Overview and Epidemiology
17.2 Current Treatment Guidelines and IO Approvals for NSCLC
17.3 Clinical Trial Activity in NSCLC
17.4 IO Marketed Product Lifecycle Development in NSCLC

18. Ovarian Cancer
18.1 Disease Overview and Epidemiology
18.2 Current Treatment Guidelines and IO Approvals for Ovarian Cancer
18.3 Clinical Trial Activity in Ovarian Cancer

19. Pancreatic Cancer
19.1 Disease Overview and Epidemiology
19.2 Current Treatment Guidelines and IO Approvals for Pancreatic Cancer
19.3 Clinical Trial Activity in Pancreatic Cancer

20. Prostate Cancer
20.1 Disease Overview and Epidemiology
20.2 Current Treatment Guidelines and IO Approvals for Prostate Cancer
20.3 Clinical Trial Activity in Prostate Cancer
20.4 IO Marketed Product Lifecycle Development in Prostate Cancer

21. Renal Cell Carcinoma (RCC)
21.1 Disease Overview and Epidemiology
21.2 Current Treatment Guidelines and IO Approvals for RCC
21.3 Clinical Trial Activity in RCC
21.4 IO Marketed Product Lifecycle Development in Multiple Myeloma

22. Appendix

Companies Mentioned

• Amgen
• AstraZeneca
• Bristol-Myers Squibb
• Dendreon Pharmaceuticals
• F. Hoffmann-La Roche
• Gilead Sciences
• Medac Pharma
• Merck & Co.
• Merck KGaA
• Northwest Biotherapeutics
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Sanofi
• Shanghai Sunway Biotech
• Shire Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/mhsh4r/immunooncology?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs , Oncology